Patents by Inventor Campbell Howard

Campbell Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ULTRARAPID ACTING INSULIN
    Publication number: 20230148019
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: December 8, 2022
    Publication date: May 11, 2023
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of ultrarapid acting insulin
    Patent number: 11559569
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 24, 2023
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20200397868
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 24, 2020
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of ultrarapid acting insulin
    Patent number: 10772935
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20180303909
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 25, 2018
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of ultrarapid acting insulin
    Patent number: 10046031
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 14, 2018
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20170143804
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 25, 2017
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of ultrarapid acting insulin
    Patent number: 9597374
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: March 21, 2017
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content
    Patent number: 8258095
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: September 4, 2012
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20120122775
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: MANNKIND CORPORATION
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • USE OF ULTRARAPID ACTING INSULIN
    Publication number: 20100035795
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Non-destructive testing of pipeline
    Patent number: 4098126
    Abstract: This invention relates to non-destructive testing of metallic pipelines using a pig having a novel way of mounting sensors for detecting any defect in the pipe wall. The sensors are mounted around the outer edge of an elastomeric cup which is rigidly fixed to the pig body. The sensors are maintained in contact with the internal surface of the pipe by a spring member which urges the sensors radially outward from the pig body.
    Type: Grant
    Filed: April 4, 1977
    Date of Patent: July 4, 1978
    Assignee: British Gas Corporation
    Inventor: David Campbell Howard